Keynote & Exhibit Pass

Keynote & Exhibit Pass offers you access to:

  • 10 PLENARY KEYNOTE PRESENTATIONS
  • KEYNOTE PANEL DISCUSSION – WOMEN IN SCIENCE
  • KEYNOTE PANEL DISCUSSION: IMPLEMENTING PRECISION MEDICINE AT BIG PHARMA

Tuesday, February 16

PLENARY KEYNOTE SESSION

POWER OF COLLABORATION IN PANDEMIC RESPONSE: ADVANCING COVID-19 MOLECULAR DIAGNOSTICS, VACCINES & BIOTHERAPEUTICS

10:55 am FDA Update on COVID-19 Molecular Diagnostic Testing
Timothy StenzelTimothy Stenzel, MD, PhD, Director, Office of In Vitro Diagnostics and Radiological Health, FDA


11:15 Sponsored Presentation
Speaker to be Announced


11:20 RADx Tech: A New Paradigm for MedTech Development
Steven SchachterSteven Schachter, MD, Professor, Neurology, Harvard Medical School; Chief Academic Officer and RADx Chief, CIMIT
On April 24, 2020, Congress appropriated $1.5 billion for SARS-CoV-2 testing to the NIH. Within 5 days after the legislation was signed into law, the NIH launched RADx Tech to support the development, production scale-up, and deployment of accurate, rapid tests across the country. One of the goals of the RADx Tech initiative was to expand capacity so that by December 2020, approximately 2% of the U.S. population (6 million persons) can be tested per day, with more tests ready for rapid deployment in proportion to national demand. During its first six months, the RADx Tech program evaluated over 700 applications and moved 22 projects into large-scale manufacturing. There are numerous unprecedented aspects of RADx Tech that make it a validated model for medtech development, as will be detailed in this presentation.

11:40 Sponsored Presentation (Opportunity Available)

11:45 From Influenza, to Ebola to Zika: How a Decade of Experience and Investments Prepared Us to Respond to This Pandemic
Robert A. JohnsonRobert A. Johnson, PhD, Influenza Director, Biomedical Advanced R&D Authority, US Department of Health & Human Services



12:05 pm Talk Title to be Announced
Helen Roberts, PhDHelen Roberts, PhD, President, Seegene Technologies


12:10 Global Public Health Consortium: A Path for Global Biosecurity through Equity and Transparency
W. Ian LipkinW. Ian Lipkin, MD, Director, Center for Infection and Immunity, Columbia University
COVID-19 has exposed our vulnerability to pandemic risk and the urgency of addressing the challenges of climate change, food security, and the viral dissemination of misinformation. New molecular diagnostic platforms, investments in wildlife, domestic animal, and human microbial surveillance, and the advent of social media tools that mine the world wide web for clues to outbreaks of infectious disease are all proving invaluable in early recognition of threats to public health. However, inequities in the distribution of resources required for diagnostics and discovery, and lack of trust and transparency remain threats to biosecurity. To address these challenges, we are establishing a global public health consortium comprising of ministries of health and academic institutions. This collaborative global program will focus on creating an infectious disease epidemiology network and has three main objectives: (1) develop a model realizing and extending the goals of the International Health Regulations established by the WHO in 2005 by providing inexpensive, rapid tools for diagnosis discovery, and surveillance of infectious diseases, (2) identify and prioritize infectious agents based on pandemic risk, and (3) share data and build the infrastructure needed to produce, validate and implement drugs and vaccines to reduce morbidity and mortality.

Wednesday, February 17

KEYNOTE PANEL DISCUSSION: WOMEN IN SCIENCE

10:30 am Women in Science

Panel Moderator:

Karen Kaul MD, PhDKaren Kaul MD, PhD, Chair, Department of Pathology and Laboratory Medicine; Duckworth Family Chair, NorthShore University HealthSystem; Clinical Professor, Pathology, University of Chicago Pritzker School of Medicine


Panelists:


Janice Chen, PhDJanice Chen, PhD, Co-Founder & CTO, Mammoth Biosciences


Malileh PoorfarhaniMalileh Poorfarhani, Director, Digital Health and R&D, Bayer


Theresa L. WhitesideTheresa L. Whiteside, PhD, Professor, Pathology, Immunology & Otolaryngology, University of Pittsburgh


PLENARY KEYNOTE SESSION

BIG PHARMA'S RESPONSE TO COVID-19: RAPID DEVELOPMENT OF VACCINES AND BIOTHERAPEUTICS

1:20 pm Exploring New Therapies for COVID-19: Focus on AstraZeneca’s Long-Acting Monoclonal Antibody Combination
Mark T. EsserMark T. Esser, PhD, Vice President, Microbial Sciences, BioPharma R&D, AstraZeneca
This talk will provide an overview of convalescent plasma and monoclonal antibodies currently in development for treating COVID-19 with a focus on the discovery and development of AstraZeneca's long-acting antibody (LAAB) combination (AZD7442) currently being evaluated for both the prevention and treatment of COVID-19.

1:40 Sponsored Presentation (Opportunity Available)

2:05 Sponsored Presentation (Opportunity Available)

2:10 Developing a COVID Vaccine in Ten Months
Sanjay GurunathanSanjay Gurunathan, MD, Vice President and Head, Global Clinical Department, Sanofi Pasteur


Thursday, February 18

PLENARY KEYNOTE SESSION

PRECISION MEDICINE AT BIG PHARMA

11:40 am Turning Science into Medicine: The Power of Collaboration
Mene N. PangalosMene N. Pangalos, PhD, Executive Vice President Biopharmaceuticals R&D, AstraZeneca
The rate of change across healthcare is more rapid than ever before and although 2020 has been challenging, it has forced us to think progressively about how we enable and execute the discovery and development of the next wave of life-changing medicines to patients. Because of the investment we have been making in transformative technologies, digital health solutions, and data science and AI in clinical trial innovation, we have enabled existing trials to continue safely and at speed through remote data collection from home. Scientists in our labs have rapidly applied their expertise in diagnostics, high-throughput screening and infectious diseases, developing new treatments and preventative approaches to combat the virus. This has shown how we can adapt quickly, work seamlessly across partners and accelerate the introduction of new ways of working to fast-forward the pace of science. Creating R&D organizations that are integrated and collaborative means we are fit for the future – whatever that may hold – and it is this strength which allows us to continue transforming science to create the greatest and swiftest impact on the diseases we aim to treat, prevent and in the future even cure.

12:00 pm Keynote Introduction
Rob Fannon, MPH, MBARob Fannon, MPH, MBA, General Manager, Biospecimen Solutions, Biospecimens, Precision for Medicine


12:05 Diagnostics at Pfizer: Enabling Precision Medicine
Hakan SakulHakan Sakul, PhD, Vice President and Head, Diagnostics, Pfizer
Many drugs have been brought to global markets by pharmaceutical companies over the years through the use of Precision Medicine approaches. Even though oncology has been the biggest beneficiary so far, other disease areas are recording progress in development of such precision medicines. Diagnostics, and in particular companion diagnostics, have been an integral part of such drug development programs. This talk will focus on progress in the use of companion diagnostics in pharma environment with particular focus on Pfizer programs, our historical approach to diagnostics, its impact on our pharma pipeline, regulatory, policy and commercialization considerations, as well as exploration of new technologies.

12:25 Sponsored Presentation (Opportunity Available)

12:40 Keynote Panel Discussion: Implementing Precision Medicine at Big Pharma

Moderator:
Cecilia Schott, PharmDCecilia Schott, PharmD, MBA, Head, Global Precision Medicine Strategy, Oncology Business Unit, Novartis


Panelists:

Hakan SakulHakan Sakul, PhD, Vice President and Head, Diagnostics, Pfizer


Maria C. M. OrrMaria C. M. Orr, PhD, FRSB, Head of Precision Medicine, Biopharmaceuticals, AstraZeneca


Masayuki Kanai, PhDMasayuki Kanai, PhD, Director & Global Companion Diagnostics Leader, Clinical Biomarkers & Translational Science, Daiichi Sankyo Inc.


Zhen Su, MD, MBAZhen Su, MD, MBA, Senior Vice President, Head of US & Global Oncology Franchise, EMD Serono, a business of Merck KGaA, Darmstadt, Germany


Rob Fannon, MPH, MBARob Fannon, MPH, MBA, General Manager, Biospecimen Solutions, Biospecimens, Precision for Medicine


Technology Presentations

Clinical Trial Assay & CDx Development in the era of Precision Medicine – Planning for Success
Katarina Wikstrom, PhD, Head of US Operations, Almac Group


SARS-CoV-2 Diagnostics by NGS: Interesting Challenges and Scalable Solutions
Jeremy Ellis, PhD, CSO, Fry Laboratories, LLC


Transforming COVID-19 Testing Through BGI/MGI Clinical Lab Partnership Program
Charles Bao, General Manager, BGI Americas


Exosome-Based Digital PCR for FGFR Assessment in Bladder Cancer
Ronny Kellner, Senior Scientist, dPCR Assay Development, dPCR Assay Development, Qiagen


Clinical Development of a Liquid Biopsy Platform to Aid in the Diagnosis and Treatment of Lung Cancer
Robert J. Mattaliano, PhD, COO, Sanmed Diagnostics Inc.


A Single-Stranded NGS Approach to cfDNA Precision Oncology for Improved Fragmentomic Analyses
Varsha Rao, Director, Clinical R&D, Claret Bioscience LLC


Rapid Analytics for Coronavirus Vaccines using the VaxArray Platform
Erica Dawson, PhD, Chief Technical Officer, InDevR


Transforming Surveillance into Analytics for Predictive Biomarkers and Clinical Diagnostics in Oncology
Mark Gramling, PhD, Director of Oncology, Larvol


Development and Commercialization of a Novel High-Throughput CRISPR-Based SARS-CoV-2 Test
Xin Miao, PhD, Director Assay Development, Mammoth Biosciences
Tim Patno, VP, Product Development, Mammoth Biosciences


Profiling Exhausted T Cells using Vectra® Polaris™ Multiplex Immunofluorescence Assay in HNSCC
Sara Pollan, PhD, Scientist, Multiplexing, NeoGenomics Laboratories


NGS Liquid Biopsy Testing for Solid Tumors: Clinical Trials and Routine Diagnostics
James Yen, PhD, Principal Scientist, Associate Scientific Director, Pharma Services, NeoGenomics Laboratories


A Rapid Lateral Flow Test Detecting SARS-CoV-2 Neutralizing Antibodies
Jianfu Wang, PhD, CEO, Innovation, Novodiax Inc.


 


Advancing Highly Multiplexed Liquid and Tissue Biopsy: Introducing RareCyte’s Orion Platform
Tad George, PhD, Sr. VP of Biology R&D, R&D, RareCyte, Inc.


The SomaScan® Assay: Biomarker Discovery to Delivery
Sheri Wilcox, PhD, Senior Director, Scientific Liaison and Technical Support, SomaLogic, Inc.


New Platform for Liquid Biopsy Enables Precise Cancer Diagnosis and CTC Clusters Detection in Early-Stage Breast Cancer
Roberta Carbone, PhD, CSO, Tethis S.p.A


How Biospecimen Sourcing Can Impact Your R&D Programs
Vanessa Tumilasci, PhD, Commercial Director, Trans-Hit Biomarkers



Premier Sponsors

10x-genomics-logo

Biodesix

Burning-Rock-Dx

NeoGenomics

Precision_for_Medicine_new



RareCyte

Seegene